IMUNON Q1 Loss $4.3M and $4.8M Cash, Phase 2 Shows 14.7-Month OS Gain
IMUNON reported a first-quarter net loss of $4.3 million and held $4.8 million in cash, covering under two quarters of operations. Final Phase 2 OVATION 2 data showed a median overall survival improvement of 14.7 months versus standard chemotherapy and a 24.2-month gain with added PARP inhibitor.
1. Final Phase 2 OVATION 2 Data
IMUNON’s completed Phase 2 OVATION 2 trial in 112 women with newly diagnosed advanced ovarian cancer demonstrated a median overall survival improvement of 14.7 months (45.1 vs. 30.4 months) compared to standard neoadjuvant and adjuvant chemotherapy. A subset receiving IMNN-001 plus chemotherapy and PARP inhibitors achieved a 24.2-month survival benefit (65.6 vs. 41.4 months), with the therapy maintaining a favorable safety and tolerability profile.
2. Phase 3 OVATION 3 Enrollment Progress
Enrollment in the pivotal Phase 3 OVATION 3 study is progressing ahead of plan, with completion targeted by Q1 2029. The FDA has reviewed and aligned on the trial protocol, confirming a clear path to Biologics License Application submission upon positive results.
3. First Quarter 2026 Financial Summary
For Q1 2026, IMUNON recorded a net loss of $4.3 million, or $0.84 per share, versus a $4.1 million loss in Q1 2025. Operating expenses totaled $4.3 million, split between $2.3 million in R&D and $2.0 million in G&A, while cash burn of $4.0 million left $4.8 million in cash and equivalents at March 31.
4. Strategic Reorganization and Outlook
In February 2026, IMUNON implemented a strategic reorganization to reduce operating expenses and focus resources on the OVATION 3 trial. Management will host a conference call on May 12 to review Q1 results and outline next steps for clinical advancement and funding strategy.